Back to search

Article

Prognostic Value of Baseline HbA1c in Advanced Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Retrospective Cohort Study

2026-01-30

Abstract excerpt

<title>Abstract</title> <p>Background Immune checkpoint blockade has become routine for advanced non-small cell lung cancer (NSCLC), but patient benefit is heterogeneous. In everyday practice, it is uncertain whether pretreatment glycemic exposure—reflected by glycosylated hemoglobin (HbA1c)—tracks with response to PD-1/PD-L1–based therapy. We therefore assessed baseline HbA1c in relation to outcomes in advanced...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
962671d7-fe2f-5cb0-8d3e-aedf1bdfc97a
DOI
10.21203/rs.3.rs-8687876/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Prognostic Value of Baseline HbA1c in Advanced Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Inhibitors: A Retrospective Cohort StudyDOI 10.21203/rs.3.rs-8687876/v1
Serum albumin as a prognostic predictor reflecting host immunity in patients with non–small cell lung cancerSemantic proximity
Association of Diabetes Status With Survival After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: a Retrospective Study in JapanSemantic proximity
Weight change and Impact on prognosis in patients with Advanced Non-small Cell Lung Cancer with Concomitant diabetes mellitus treated with SGLT2 inhibitorsSemantic proximity
Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanomaSemantic proximity
Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade.Semantic proximity
A Latent Class Analysis Based on Nutritional and Inflammatory Profiles Predicts Efficacy in Advanced NSCLC Treated with Immune Checkpoint InhibitorsSemantic proximity
Baseline anemia predicts a poor prognosis in patients with non-small cell lung cancer with epidermal growth factor receptor mutations: a retrospective study.Semantic proximity
Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy.Semantic proximity
Pretreatment HDL-C and ApoA1 are predictive biomarkers of progression-free survival in patients with EGFR mutated advanced non-small cell lung cancer treated with TKI.Semantic proximity
PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.Semantic proximity
Levels of Pretreatment Blood Lipids are Prognostic Factors in Advanced NSCLC Patients Treated with AnlotinibSemantic proximity
The Impact of Comorbidities, Neutrophil-to-lymphocyte Ratio, and Adverse Events on Quality of Life in Lung Cancer Patients Receiving EGFR-TKI TherapySemantic proximity
Select a neighboring publication to make it the new centre.